In the context of a recent clinical trial that showed the benefit of trametinib treatment in ovarian cancer, our studies warn of a potential refinement of trametinib therapy by taking into account the WNK1–ERK5 route in future ovarian cancer precision treatment regimens. This evidence concerns the gene MAPK7 and ovarian carcinoma.